Waters Corporation

NYSE WAT

Data sourced from

and

Download Data

Waters Corporation Return on Common Equity 3 year CAGR for the year ending December 31, 2021: 4.93%

Waters Corporation Return on Common Equity 3 year CAGR is 4.93% for the year ending December 31, 2021, a -97.46% change year over year. Return on common equity measures the profitability of a company relative to its common shareholders' equity. It is calculated by dividing the net income by the common stock (net). This ratio indicates how effectively a company generates profit for its common shareholders' equity investment. A higher return on common equity suggests better profitability and value creation for common shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Waters Corporation Return on Common Equity for the year ending December 31, 2021 was 42,741.70%, a 32.51% change year over year.
Waters Corporation Return on Common Equity for the year ending December 31, 2020 was 32,255.47%, a -12.31% change year over year.
Waters Corporation Return on Common Equity for the year ending December 31, 2019 was 36,782.48%, a -0.58% change year over year.

NYSE: WAT

Waters Corporation

CEO	Dr. Udit Batra Ph.D.
IPO Date	Nov. 16, 1995
Location	United States
Headquarters	34 Maple Street, Milford, MA, United States, 01757
Employees	7,900
Sector	Healthcare
Industry	Diagnostics & research

Description

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Key trends